Dasatinib in chronic myelogenous leukemia [2]

New England Journal of Medicine

Volumn 355, Issue 10, 2006, Pages 1062-1063

  Chu, Sung Chao ^a   Tang, Jih Luh ^b   Li, Chi Cheng ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; IMATINIB; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; ABL BCR FUSION PROTEIN, HUMAN; ABL-BCR FUSION PROTEIN, HUMAN; PIPERAZINE DERIVATIVE;

CARBOXY TERMINAL SEQUENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA SPLICING; DRUG STRUCTURE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LETTER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STOP CODON; CHEMICALLY INDUCED DISORDER; MYELOID LEUKEMIA; NOTE; PARACENTESIS; PLEURA EFFUSION; PLEURODESIS; ADULT; CASE REPORT; CHEMISTRY; DRUG RESISTANCE; GENETICS; MALE; MUTATION; ONCOGENE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PARACENTESIS; PLEURAL EFFUSION; PLEURODESIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; ADULT; BASE SEQUENCE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENES, ABL; LEUKEMIA, MYELOID, CHRONIC; MALE; MUTATION; PIPERAZINES;

EID: 33748416343     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061882     Document Type: Letter

References (2)

1. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
2. Tokarski JS, Newitt J, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7.